AstraZeneca antibody cocktail trials show it can halve risk of severe disease, prevent, treat Covid
AstraZeneca's antibody drug cut the risk of severe Covid-19 by at least 50% in a late stage study, the company announced on Monday. The injection, called AZD7442, contains two different antibodies developed from the the blood of people who previously contracted Covid-19. It's the drug first of its kind shown to both prevent and treat Covid-19 in late-stage trials, the company said in a press release. The company has already requested Food and Drug Administration (FDA) approval to use AZD7442 to prevent Covid-19, after late-stage trial results in August showed it reduced the risk of Covid-19 with symptoms by 77%.
Business Insider - October 11, 2021View the full story here: https://www.businessinsider.co.za/astrazeneca-antibody-drug-azd7442-reduced-severe-covid-19-risk-study-2021-10